TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3309196

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy (4,500 cGy in 5 weeks)
Number of subjects: 510

Group type: COMPARATOR
Intervention: Chemotherapy only
Number of subjects: 510

Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Number of subjects: 510
Study: 31563628

Group type: EXPERIMENTAL
Intervention: 1% lidocaine paracervical block
Number of subjects: 93

Group type: COMPARATOR
Intervention: Sham paracervical block
Number of subjects: 93
Study: 29797436

Group type: COMPARATOR
Intervention: Scaling and root planing (SRP) alone
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with metronidazole (MTZ; 400 mg/TID for 14 days)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Scaling and root planing (SRP) combined with metronidazole (MTZ; 400 mg/TID for 14 days) and amoxicillin (AMX; 500 mg/TID for 14 days)
Number of subjects: 59
Study: 27535654

Group type: EXPERIMENTAL
Intervention: Manual pressure applied at the vaccination site for 10 seconds before injection
Number of subjects: 123

Group type: COMPARATOR
Intervention: Standard injection technique without manual pressure
Number of subjects: 123
Study: 24823599

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg, q.d.
Number of subjects: 279

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 279
Study: 23839593

Group type: EXPERIMENTAL
Intervention: Program combining pre-authorization requirement and systematic post-prescription review of carbapenems
Number of subjects: 337

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 337
Study: 20482957

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 267
Study: 18201915

Group type: EXPERIMENTAL
Intervention: MRA
Number of subjects: 197

Group type: COMPARATOR
Intervention: DSA
Number of subjects: 197
Study: 16553578

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 0
Study: 14501599

Group type: EXPERIMENTAL
Intervention: Testosterone therapy (10 mg/day testosterone cream)
Number of subjects: 34
Study: 11103826

Group type: EXPERIMENTAL
Intervention: Psychological therapy, relaxation training, and stress management
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychosocial interventions (from a meta-analysis of 23 randomised trials)
Number of subjects: 0
Study: 8668779

Group type: EXPERIMENTAL
Intervention: Warmed ionic contrast medium with nonsodium pure meglumine as the cation
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Warmed ionic contrast medium with sodium meglumine as the cation
Number of subjects: 4936

Group type: EXPERIMENTAL
Intervention: Warmed nonionic iopamidol
Number of subjects: 4936

Group type: COMPARATOR
Intervention: Ionic contrast medium at ambient temperature
Number of subjects: 4936
Study: 1727784

Group type: EXPERIMENTAL
Intervention: Motilin (10 pmol.kg‐1.min‐1)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 6
Study: 6146821

Group type: EXPERIMENTAL
Intervention: Ranitidine 150 mg twice daily
Number of subjects: 102

Group type: COMPARATOR
Intervention: Ranitidine 300 mg every evening
Number of subjects: 102
Study: 31992513

Group type: COMPARATOR
Intervention: AF burden <0.5%
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AF burden ≥0.5%
Number of subjects: 30
Study: 30463520

Group type: EXPERIMENTAL
Intervention: Caregiver gender
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Patient treatment modality
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Hospital type
Number of subjects: 737

Group type: COMPARATOR
Intervention: Reasons for non-participation
Number of subjects: 737

Group type: COMPARATOR
Intervention: Factors associated with non-participation reasons
Number of subjects: 737

Group type: COMPARATOR
Intervention: Specific patient characteristics
Number of subjects: 737

Group type: COMPARATOR
Intervention: Age-related decline reasons
Number of subjects: 737

Group type: COMPARATOR
Intervention: Burden-related decline reasons
Number of subjects: 737
Study: 26197721

Group type: EXPERIMENTAL
Intervention: Plyometric training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study: 25244479

Group type: EXPERIMENTAL
Intervention: Beat the Blues (BTB) intervention
Number of subjects: 208

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 208
Study: 23185750

Group type: EXPERIMENTAL
Intervention: QM + chemotherapy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Pure chemotherapy (control group)
Number of subjects: 120
Study: 19858256

Group type: EXPERIMENTAL
Intervention: Levofloxacin 7 mg/kg body weight
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Levofloxacin 8 mg/kg twice a day
Number of subjects: 90

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg and 750 mg in healthy adults
Number of subjects: 90
Study: 18076245

Group type: EXPERIMENTAL
Intervention: 10 drop jumps (DJs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: 50 drop jumps (DJs)
Number of subjects: 16
Study: 16227840

Group type: EXPERIMENTAL
Intervention: Moxifloxacin hydrochloride ophthalmic solution, 0.5% - 1 drop every 15 minutes for 4 doses before surgery (group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moxifloxacin hydrochloride ophthalmic solution, 0.5% - 1 drop 4 times per day on the day before surgery plus the same preoperative regimen as group 1 (group 2)
Number of subjects: 60
Study: 12382950

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (1500 pulses ESWT at 0.12 mJ/mm2)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 75
Study: 11369909

Group type: EXPERIMENTAL
Intervention: Education only
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Education plus environmental changes
Number of subjects: 176

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 176
Study: 9272102

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement at 0.024 mg/kg per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement at 0.012 mg/kg per day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) replacement (both doses)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Patients continuing GH therapy
Number of subjects: 42
Study: 8257527

Group type: EXPERIMENTAL
Intervention: Somatostatin analog SMS 201-995 (SMS) at doses ranging from 0.8-2.2 micrograms/kg sc
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Somatostatin analog SMS 201-995 (SMS) at standard doses of 1 microgram/kg sc
Number of subjects: 37
Study: 3001518

Group type: EXPERIMENTAL
Intervention: Intranasal alpha 2-interferon
Number of subjects: 120
Study: 31587317

Group type: EXPERIMENTAL
Intervention: Intraorifice barrier group (glass-ionomer cement barrier + GIC base + composite resin restoration)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Base group (2-mm-thick GIC base + composite resin restoration)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (pulp chamber filled with composite resin only)
Number of subjects: 120
Study: 29415851

Group type: EXPERIMENTAL
Intervention: Nutrition intervention (two lectures on healthy nutrition followed by weight monitoring over 6 weeks)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control (weighed at baseline, post-lectures and at study closure)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 89
Study: 27531732

Group type: EXPERIMENTAL
Intervention: Targeted ADL programme delivered by an occupational therapist (in addition to usual care)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care (6 weeks of homecare reablement delivered by social care workers)
Number of subjects: 30
Study: 25940353

Group type: EXPERIMENTAL
Intervention: School-based scheme for diagnosis and treatment of schistosomiasis mansoni
Number of subjects: 0

Group type: COMPARATOR
Intervention: Community-based scheme for diagnosis and treatment of schistosomiasis mansoni
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of positives for Schistosoma mansoni with praziquantel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment of positives for soil-transmitted helminthes (STH) with mebendazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional status assessment of positives for S. mansoni
Number of subjects: 0
Study: 23080288

Group type: EXPERIMENTAL
Intervention: Hib-MenC-TT vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hib plus MCC vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 21134613

Group type: EXPERIMENTAL
Intervention: Collagenase (0.58 mg)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 18197912

Group type: EXPERIMENTAL
Intervention: IL-8 measurement in pleural fluid at a cutoff value of 1000 pg/mL
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CRP measurement in pleural fluid at a cutoff value of 80 mg/L
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pleural fluid tests (including pH, glucose, LDH, IL-8, and CRP)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multivariate analysis of pleural fluid parameters
Number of subjects: 100
Study: 17313855

Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF 100 microg/kg (single subcutaneous injection on day 3)
Number of subjects: 104

Group type: COMPARATOR
Intervention: rhG-CSF 5 microg x kg(‐1) x d(‐1) (daily subcutaneous injection starting on day 3 for 14 days)
Number of subjects: 104
Study: 14728105

Group type: EXPERIMENTAL
Intervention: Baclofen (20 mg t.i.d.)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 11022077

Group type: EXPERIMENTAL
Intervention: Prothrombotic risk factors
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Increased Lp(a) level (>30 mg/dL)
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: FV G1691A mutation
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: PT G20210A variant
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: MTHFR TT677 genotype
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Protein C type I deficiency
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Acquired IgG ACAs
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: Additional triggering factors (asphyxia, septicemia, maternal diabetes, renal venous thrombosis)
Number of subjects: 273
Study: 8828247

Group type: COMPARATOR
Intervention: medication only, no contingencies
Number of subjects: 353

Group type: COMPARATOR
Intervention: standard counseling, no contingencies
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: enhanced services, contingency contracting
Number of subjects: 353

Group type: COMPARATOR
Intervention: non-contingent conditions
Number of subjects: 353
Study: 1441947

Group type: EXPERIMENTAL
Intervention: Growth hormone-loaded PMMA (20 mg of growth hormone)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cemented or cementless hip replacement without added growth hormone (Control)
Number of subjects: 30
Study: 30269002

Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Script-Driven Imagery (SDI)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 127
Study: 26755219

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BioAggregate
Number of subjects: 20
Study: 24433126

Group type: EXPERIMENTAL
Intervention: Pairing steamed broccoli with cheese pizza for lunch
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Enhancing visual appeal of raw cucumber as semicircles with chive and olive garnish
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Enhancing visual appeal of raw cucumber arranged in a visually appealing manner (in the shape of a caterpillar)
Number of subjects: 57
Study: 23161338

Group type: EXPERIMENTAL
Intervention: Aerobic exercise (cycling) for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Table football (control)
Number of subjects: 0
Study: 19406399

Group type: EXPERIMENTAL
Intervention: Hysteroscopic myomectomy (n = 101)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Diagnostic hysteroscopy and myoma biopsy (n = 103)
Number of subjects: 215
Study: 19463299

Group type: EXPERIMENTAL
Intervention: TriActiv System (Kensey‐Nash Corp.)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Guardwire (Medtronic)
Number of subjects: 631

Group type: COMPARATOR
Intervention: Filterwire (Boston Scientific)
Number of subjects: 631
Study: 15936468

Group type: EXPERIMENTAL
Intervention: Glimepiride (doses equivalent to gliclazide 40 mg = glimepiride 1 mg, glibenclamide 2.5 mg = glimepiride 2 mg)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Conventional SU (gliclazide or glibenclamide, no change in treatment)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 172
Study: 12921927

Group type: EXPERIMENTAL
Intervention: Nurses
Number of subjects: 150

Group type: COMPARATOR
Intervention: Urologic Surgeons
Number of subjects: 150
Study: 10802396

Group type: EXPERIMENTAL
Intervention: Physical exercise
Number of subjects: 57
Study: 8874326

Group type: EXPERIMENTAL
Intervention: IFN alpha 2a (9 million IU) subcutaneously three times weekly with 5‐FU (750 mg/m2/d) by continuous intravenous infusion on days 1 to 5 and then weekly IV bolus at the same dose
Number of subjects: 245

Group type: COMPARATOR
Intervention: 5‐FU alone at the same dose schedule
Number of subjects: 245
Study: 1642918

Group type: EXPERIMENTAL
Intervention: Crystalloid preload 20 ml kg‐1 over 10 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Crystalloid preload 20 ml kg‐1 over 20 min
Number of subjects: 20
Study: 6541254

Group type: EXPERIMENTAL
Intervention: Sheehy Collar Button tube
Number of subjects: 939
Study: 31407320

Group type: EXPERIMENTAL
Intervention: CHOP-14 scheme with rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: CHOP-14 scheme without rituximab
Number of subjects: 0
Study: 29241615

Group type: EXPERIMENTAL
Intervention: Intervention (medical supply kits, cupboard for storage, tracking sheet, one-day training session)
Number of subjects: 218277
Study: 27374220

Group type: EXPERIMENTAL
Intervention: Endobronchial valves (EBV) placement
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 24650832

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for insomnia (CBTI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Behavioral placebo treatment (BPT)
Number of subjects: 56
Study: 22584558

Group type: EXPERIMENTAL
Intervention: Lidocaine (1.5 mg/kg bolus followed by a 2 mg/kg/h infusion until the end of the surgical procedure)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Saline (placebo)
Number of subjects: 70
Study: 21526667

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% (B group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (S group, placebo group)
Number of subjects: 40
Study: 16531614

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) + Vitamin B12 (0.4 mg)
Number of subjects: 3749

Group type: EXPERIMENTAL
Intervention: Vitamin B6 (40 mg)
Number of subjects: 3749

Group type: EXPERIMENTAL
Intervention: Folic acid (0.8 mg) + Vitamin B12 (0.4 mg) + Vitamin B6 (40 mg)
Number of subjects: 3749

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3749
Study: 14509561

Group type: EXPERIMENTAL
Intervention: Formoterol 4.5 microg as needed
Number of subjects: 362

Group type: COMPARATOR
Intervention: Terbutaline 500 microg as needed
Number of subjects: 362
Study: 10694782

Group type: EXPERIMENTAL
Intervention: Cocoa butter (30.7 g/d) consumed in the form of black chocolate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Corn oil (control)
Number of subjects: 12
Study: 9380281

Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg, single oral dose)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisapride combined with ACTH
Number of subjects: 0
Study: 8096475

Group type: EXPERIMENTAL
Intervention: 5% glucose infusion
Number of subjects: 164

Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control group (no oxytocin infusion)
Number of subjects: 164
Study: 2864051

Group type: EXPERIMENTAL
Intervention: Nadolol 80 mg once daily
Number of subjects: 10
Study: 31916036

Group type: EXPERIMENTAL
Intervention: Sage-containing mouthwash
Number of subjects: 48

Group type: COMPARATOR
Intervention: Water/alcohol-based placebo
Number of subjects: 48
Study: 31073188

Group type: EXPERIMENTAL
Intervention: APO-assisted training program
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (traditional self-paced overground walking)
Number of subjects: 10
Study: 28105902

Group type: EXPERIMENTAL
Intervention: Adjunctive porcine small intestine submucosa (SIS; Oasis Ultra)
Number of subjects: 0
Study: 25583029

Group type: EXPERIMENTAL
Intervention: Web-based simulation for 3 hours
Number of subjects: 67
Study: 24162940

Group type: EXPERIMENTAL
Intervention: Paracetamol
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Combination of ibuprofen and paracetamol
Number of subjects: 889
Study: 21865791

Group type: EXPERIMENTAL
Intervention: PMMA-CHDF
Number of subjects: 43

Group type: COMPARATOR
Intervention: PAN-CHDF
Number of subjects: 43
Study: 19466669

Group type: EXPERIMENTAL
Intervention: Ephedrine (50 mg taken 1 hour prior to sexual activity)
Number of subjects: 19

Group type: COMPARATOR
Intervention: SSRIs (sertraline, paroxetine)
Number of subjects: 19

Group type: COMPARATOR
Intervention: SSRIs (fluoxetine)
Number of subjects: 19
Study: 17297553

Group type: EXPERIMENTAL
Intervention: Lateral internal sphincterotomy
Number of subjects: 82

Group type: COMPARATOR
Intervention: Topical nitroglycerin
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 15199624

Group type: EXPERIMENTAL
Intervention: SQNYCH combined with chemotherapy
Number of subjects: 114

Group type: COMPARATOR
Intervention: Western medicine only
Number of subjects: 114
Study: 12397048

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 9523211

Group type: EXPERIMENTAL
Intervention: Inheritance of shared epitope (SE) alleles
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Genotype model of SE alleles
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 2 SE copies
Number of subjects: 180
Study: 7535842

Group type: EXPERIMENTAL
Intervention: Granulocyte colony-stimulating factor (G-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granulocyte-macrophage colony-stimulating factor (GM-CSF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other cytokines (M-CSF, IL-3, PIXY321, SCF, IL-1, IL-6, IL-11)
Number of subjects: 0
Study: 2692962

Group type: EXPERIMENTAL
Intervention: HRP112 (depot‐medroxyprogesterone acetate, 25 mg and estradiol cypionate, 5 mg)
Number of subjects: 2320

Group type: COMPARATOR
Intervention: HRP102 (norethisterone enantate, 50 mg and estradiol valerate, 5 mg)
Number of subjects: 2320
Study: 336002

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5-HTP) in combination with Benzerazide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (L-5-HTP)
Number of subjects: 30
Study: 30989165

Group type: EXPERIMENTAL
Intervention: Virtual Interactive Working Memory Training (VIMT), n = 33, 45 min sessions 3 times per week for a total of 36 sessions
Number of subjects: 66

Group type: COMPARATOR
Intervention: Active control group, n = 33, 45 min sessions 3 times per week for a total of 36 sessions
Number of subjects: 66
Study: 27784634

Group type: EXPERIMENTAL
Intervention: Creamy soundtrack
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rough soundtrack
Number of subjects: 0
Study: 26247351

Group type: EXPERIMENTAL
Intervention: Micro-capsules containing menthol/PCL
Number of subjects: 10
Study: 22975664

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel plus cilostazol (intensification group, n = 72)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Aspirin and clopidogrel (control group, n = 74)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel plus cilostazol (intensification group)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Aspirin and clopidogrel (control group)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 146
Study: 21906885

Group type: EXPERIMENTAL
Intervention: High stress group
Number of subjects: 59

Group type: COMPARATOR
Intervention: Low stress group
Number of subjects: 59
Study: 19558562

Group type: EXPERIMENTAL
Intervention: 5-ASA (1.5 g for 1 year)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: E. coli Nissle (EcN)
Number of subjects: 39
Study: 16122956

Group type: EXPERIMENTAL
Intervention: Valdecoxib (40 mg) given orally for 4 days prior to oesophageal acid infusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IV Parecoxib (40 mg) given 120 min after oesophageal acid infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo given orally for 4 days prior to oesophageal acid infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline given IV 120 min after oesophageal acid infusion
Number of subjects: 0
Study: 15513550

Group type: EXPERIMENTAL
Intervention: Daily nasal spray with physiological saline
Number of subjects: 108
Study: 11176172

Group type: EXPERIMENTAL
Intervention: Normal monocytes incubated with septic serum
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normal monocytes incubated with septic serum and anti-IL-10 antibodies
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Normal monocytes incubated with anti-TGF-beta antibodies
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Septic monocytes stimulated with endotoxin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls stimulated with endotoxin
Number of subjects: 20
Study: 9472123

Group type: EXPERIMENTAL
Intervention: Actigraphic monitoring in children with ADHD
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal controls (N=12)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subjective parental reports
Number of subjects: 12
Study: 9316690

Group type: EXPERIMENTAL
Intervention: Flunarizine (FZ) 20 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cinnarizine (CZ) 150 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 2898422

Group type: EXPERIMENTAL
Intervention: olsalazine 500 mg bd
Number of subjects: 164

Group type: COMPARATOR
Intervention: sulphasalazine 1 g bd
Number of subjects: 164